Canocapavir Is a Novel Capsid Assembly Modulator Inducing a Conformational Change of the Linker Region of HBV Core Protein

Canocapavir is a novel antiviral agent with characteristics of core protein allosteric modulators (CpAMs) that is currently in a phase II clinical trial for treatment of hepatitis B virus (HBV) infection. Herein, we show that Canocapavir prevented the encapsidation of HBV pregenomic RNA and increase...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Yuan, Yang, Le, Yu, Lin, Zhu, Yuanfei, Wu, Yang, Zhang, Zhijun, Xia, Tian, Deng, Qiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10223407/
https://www.ncbi.nlm.nih.gov/pubmed/37243280
http://dx.doi.org/10.3390/v15051195

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10223407/
https://www.ncbi.nlm.nih.gov/pubmed/37243280
http://dx.doi.org/10.3390/v15051195

Ejemplares similares